Goldman Unit Buys €2 Billion Drugmaker Synthon From BC Partners

Goldman Sachs Group Inc.’s alternative investment arm has agreed to buy a majority stake in Dutch generic drugmaker Synthon from BC Partners.

BC Partners will keep a minority holding in Synthon to support future growth, according to a statement Monday, which confirmed an earlier Bloomberg News report. It didn’t provide financial details.

Bloomberg News reported earlier that the Goldman unit had beat out other suitors for Synthon and could value the drugmaker at about €2 billion ($2.1 billion).

Founded in 1991, Synthon International develops and manufactures generic drugs for therapeutic areas including oncology, central nervous system and ...